CAMBRIDGE, Mass., Dec. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced the election
of Richard W. Dugan to the Company's Board of Directors. His appointment
increases Xanthus' board to five members, including four non-employee
directors.
Mr. Dugan has a distinguished business background, having served as a
Partner with Ernst & Young, LLP from 1976 to 2002. While with the firm, Mr.
Dugan held a variety of managing and senior partner positions, including Mid-
Atlantic Area Senior Partner, Mid-Atlantic Area Managing Partner, and
Pittsburgh Office Managing Partner. Mr. Dugan retired from Ernst & Young LLP
in September, 2002
"Dick brings to Xanthus significant financial and strategic experience in
helping guide businesses to evolve from early-stage development companies to
broader, publicly-traded corporate enterprises," stated Richard T. Dean, Ph.D.,
President and CEO of Xanthus. "Dick's understanding of the unique issues
confronting rapidly-evolving biopharmaceutical companies complements the
skills and experience of our current board members at this important stage of
our corporate development."
Mr. Dugan received a B.S.B.A. from Pennsylvania State University. He
currently serves as a Board Member and Chair of the Audit Committee for
Advancis Pharmaceutical Corporation (Germantown, MD), and Critical
Therapeutics, Inc. (Lexington, MA). Both firms are publicly traded on NASDAQ.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-
stage, small-molecule oncology drugs through a management team whose
accomplished track record encompasses all aspects of drug development, from
discovery through regulatory approval and commercialization. The Company is
applying its expertise both to advance its current pipeline and expand it into
indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. -
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences,
Inc. - john.mccarthy@xanthus.com or (617) 225-0522, x 125
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1- 508-647-0209, kwatson@macbiocom.com; or
John A. McCarthy, Jr., Senior Vice President & CFO of Xanthus
Life Sciences, Inc., +1-617-225-0522, ext. 125,
john.mccarthy@xanthus.com
|
